Αποτελέσματα Αναζήτησης
15 Ιουν 2024 · Heart- and lung-related symptoms When scleroderma affects the heart or lungs, it can cause shortness of breath, decreased exercise tolerance and dizziness. Scleroderma can cause scarring in the lung tissues that may result in increasing shortness of breath over time.
15 Ιαν 2024 · People who have interstitial lung disease along with systemic sclerosis are much more likely to die from disease complications than people who do not have lung disease. Around 80% to 90% are alive five years after being diagnosed with interstitial lung disease from systemic sclerosis.
15 Ιουλ 2017 · The 5-year mortality for patients with progressive systemic sclerosis and ILD have a survival of 82–90% in 5 years, with ILD or pulmonary hypertension being responsible for 60% of the mortality observed in such cases [5].
Up to half of people living with systemic sclerosis will have some form of lung involvement, meaning that their condition is affecting the lungs and how well they are able to function. In many cases, lung involvement will be limited in its extent and remain stable, causing symptoms only on exertion and often requiring no specific treatment.
2 Ιαν 2024 · The spectrum of pulmonary complications of SSc and an approach to their evaluation will be reviewed here. The clinical manifestations, diagnosis, therapy, and prognosis of SSc-associated ILD and PAH are discussed separately.
Pulmonary involvement in systemic sclerosis In scleroderma, the two most common types of direct pulmonary involvement are ILD and PH, which together account for 60% of SSc-related deaths [2].
Summary. Scleroderma is a multisystem disease characterized by a severe inflammatory process and exuberant fibrosis. Lung involvement is a frequent complication and a leading cause of morbidity and mortality in this syndrome.
